Clinical Trial Update: Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version [Phase 4]

View source ↗

Summary

Phase 4 clinical trial exploring erythromycin as a readthrough agent for APC gene stop-codon mutations in minors with familial adenomatous polyposis; current st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• ERYTHROMYCIN (ERYTHROMYCIN)

Snippet

Sponsor: michal roll | Conditions: FAP-Familial Adenomatous Polyposis | Phase 4 | Status: UNKNOWN